Advertisement
The presentation will be webcast live and can be accessed through theprovided link:
http://www.wsw.com/webcast/rrshq14/tbio.ob/
About Transgenomic
Advertisement
Transgenomic (OTC-Bulletin Board: TBIO.OB) is a global biotechnologycompany specializing in high sensitivity genetic variation and mutationanalysis. The Company provides products and services in the fields ofpharmacogenomics and pharmacogenetics.
Product offerings include the WAVE(R) DHPLC Systems and associatedconsumables specifically designed for use in genetic variation detection andsingle- and double-strand DNA/RNA analysis and purification. With broadapplicability to genetic research, over 1600 systems have been shipped tocustomers in more than 30 countries. The SURVEYOR(R) Mutation Detection Kitsand SURVEYOR Check-It Kit provide reagents and protocols for the detection ofmutations in DNA. In addition, HANABI automated chromosome harvesting systemsimprove laboratory productivity with consistent quality compared to manualmethods.
Service offerings include the Transgenomic Clinical Reference Laboratory,which provides reference laboratory services specializing in moleculardiagnostics including Mitochondrial Disorders, Oncology and Hematology,Molecular Pathology and Inherited Diseases. Transgenomic Genomic ResearchServices is a CRO for pharmacogenomic, translational research and clinicaltrials. For more information about the innovative systems, products andservices offered by Transgenomic, please visit: http://www.transgenomic.com.
Transgenomic Cautionary Statements
Certain statements in this press release constitute "forward-lookingstatements" of Transgenomic within the meaning of the Private SecuritiesLitigation Reform Act of 1995, which involve known and unknown risks,uncertainties and other factors that may cause our actual results to bematerially different from any future results, performance or achievementsexpressed or implied by such statements. Forward-looking statements include,but are not limited to, those with respect to management's current views andestimates of future economic circumstances, industry conditions, companyperformance and financial results, including the ability of the Company togrow its involvement in the diagnostic products and services markets. Theknown risks, uncertainties and other factors affecting these forward-lookingstatements are described from time to time in Transgenomic's reports to theSecurities and Exchange Commission. Any change in such factors, risks anduncertainties may cause the actual results, events and performance to differmaterially from those referred to in such statements. Accordingly, the companyclaims the protection of the safe harbor for forward-looking statementscontained in the Private Securities Litigation Reform Act of 1995 with respectto all statements contained in this press release. All information in thispress release is as of the date of the release and Transgenomic does notundertake any duty to update this information, including any forward-lookingstatements, unless required by law.Event: Rodman & Renshaw 10th Annual Healthcare Conference Date: Wednesday, November 12, 2008 Time: 2:00 p.m. ET Place: New York Palace Hotel, Adams (4th Floor)
SOURCE Transgenomic
